This trial is testing a monoclonal antibody called SEA-BCMA. Researchers want to know what dose is safest, what side effects patients may have, and if SEA-BCMA will work to treat multiple myeloma.
SEA-BCMA is a type of treatment called a monoclonal antibody. Antibodies are part of your immune system. Usually, they help protect you from getting sick. With SEA-BCMA, researchers are using an antibody designed to stick to the multiple myeloma cells in your body. The antibody sends a signal to other cells in your immune system that kill the cancer cells. It also stops the multiple myeloma cells from getting a signal that makes them grow. The antibody may also stick to some non-cancer cells in your body.
They are asking you to be in this study because you have multiple myeloma that has come back or did not get better with your last therapy.
This trial is currently open and accepting patients.
This is a Phase 1b dose exploration and expansion study. The study is evaluating the safety, tolerability and efficacy of SEA-BCMA by itself, and when combined with Dexamethasone.
The dose expansion part of this study is being conducted in multiple parts, Part B (SEA-BCMA monotherapy), Part C (SEA-BCMA and Dexamethasone), and Part D (SEA-BCMA, Pomalidomide and Dexamethasone). This trial is open label, which means that both you and the researchers running the study will know what therapies you will receive.
Part B (SEA-BCMA Monotherapy)
This part of the study is evaluating the safety and tolerability of SEA-BCMA when given by itself. There are two phases in this part of the study, induction and maintenance therapy. This part of the study may enroll up to 40 patients.
Part C (SEA-BCMA and Dexamethasone)
This part of the study is evaluating the safety and tolerability of SEA-BCMA when combined with Dexamethasone. This part of the study is organized into two groups (cohorts) with different dosing schedules.
Part D (SEA-BCMA, Pomalidomide and Dexamethasone)
This part of the study is organized into 28 day cycles. Patients will receive SEA-BCMA (by intravenous infusion) every two weeks, Pomalidomide (by mouth) every day on days 1-21, and Dexamethasone (either by mouth or intravenous infusion) weekly.
How Will The Study Treatment Be Administered?
If your study doctor decides you can be in the study, you can start treatment. SEA-BCMA will be given to you as a liquid into a vein, called an intravenous (IV) “infusion.” The treatment will be administered at the assigned dose every 2 weeks (or every 4 weeks if recommended).
We will treat you on 1 of these treatment schedules:
During the study, Seattle Genetics will pay for:
You or your insurance company will be billed for your regular medical care. It's possible your insurance may not cover all of your regular medical care costs. You are responsible for the part your insurance doesn’t pay. If you’re not sure how this applies to you, ask your doctor or the study staff.
You won’t be paid for taking part in this study or for any discoveries made in this study.
You may be able to have some of your costs for taking part in the study paid back, like travel and lodging. Please call SparkCures at (888) 828-2206 or ask someone from the study staff for more information.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 131 patients (estimated)View More
View all clinical trial locations sorted by state.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message